Olmesartan/Hydrochlorothiazide Stada (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil blocks the AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide promotes the excretion of sodium and water by inhibiting reabsorption in the distal tubule. Together they lower vascular resistance and plasma volume, producing an additive antihypertensive effect.

The prescribed dose is determined by the treating physician based on the patient’s blood‑pressure goals, renal function, and response to therapy. Dosage adjustments are made according to clinical response and tolerability, following local prescribing guidelines.

Use during pregnancy is generally avoided because angiotensin‑II receptor blockers can affect fetal development. Breastfeeding mothers should consult a healthcare professional, as the drug may pass into breast milk and its safety for the infant has not been fully established.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy ARBs or thiazides, the fixed‑dose combination offers convenient dosing and synergistic blood‑pressure reduction, often reducing the need for multiple pills. It is an alternative to other ARB‑diuretic combos such as losartan/hydrochlorothiazide, with a similar efficacy profile but differing pharmacokinetic properties.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid exposure to extreme heat or humidity.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a full glass of water and do not crush or split it unless specifically instructed.

Serious adverse events can include severe hypotension, acute kidney injury, hyperkalemia, angio‑edema and significant electrolyte disturbances. Patients should be monitored for signs of these conditions, especially during treatment initiation or dose changes.

The combination is contraindicated in individuals with known hypersensitivity to olmesartan, hydrochlorothiazide, or any component of the formulation, as well as in patients with severe renal impairment, hyperkalemia, or anuria. It should also be avoided in pregnancy unless clearly indicated.